Disappointing results for renal denervation

The makers of the Symplicity catheter-based renal denervation device for resistant hypertension say the product will continue to be available in Australia despite negative results in a key US trial.

Medtronic announced last week that the SYMPLICITY HTN-3 trial failed to meet its primary efficacy endpoint of reducing BP in patients with uncontrolled hypertension.

The study, which followed pilot trials conducted in Australia, involved 535